Compare TCRT & CELZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCRT | CELZ |
|---|---|---|
| Founded | 1998 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 7.0M |
| IPO Year | N/A | N/A |
| Metric | TCRT | CELZ |
|---|---|---|
| Price | $2.45 | $1.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 27.3K | ★ 136.2K |
| Earning Date | 11-14-2025 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $6,000.00 | $6,000.00 |
| Revenue This Year | $5,680,500.00 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.31 | $1.50 |
| 52 Week High | $6.20 | $6.90 |
| Indicator | TCRT | CELZ |
|---|---|---|
| Relative Strength Index (RSI) | 33.42 | 43.07 |
| Support Level | $2.60 | $1.95 |
| Resistance Level | $3.02 | $2.12 |
| Average True Range (ATR) | 0.17 | 0.16 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 10.43 | 28.40 |
Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.
Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.